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Available online 16 April 2016Several novel chelators based on 1-hydroxy-2(1H)-pyridinone coordinating groups decorating a triazamacrocy-
clic backbone scaffoldwere synthesised as potential powerful Fe3+ chelators capable of competingwith bacterial
siderophores. In particular, a novel chloromethyl derivative of 1-hydroxy-2(1H)-pyridinone exploiting a novel
protective group for this family of coordinating groups was developed. These are the ﬁrst examples of
hexadentate chelators based on 1-hydroxy-2(1H)-pyridinone to be shown to have a biostatic activity against a
range of pathogenic bacteria. Their efﬁcacy as biostatic agents was assessed revealing that minor variations in
the structure of the chelator can affect efﬁcacy profoundly. The minimal inhibitory concentrations of our
best tested novel chelators approach or are comparable to those for 1,4,7-tris(3-hydroxy-6-methyl-2-
pyridylmethyl)-1,4,7-triazacyclononane, the best Fe3+ chelator known to date. The retarding effect these
chelators have onmicrobial growth suggests that they could have a potential application as a co-active alongside
antibiotics in the ﬁght against infections.
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Bacterial resistance to once effective antibiotics has emerged as a
major health threat of the 21st century [1,2]. There is therefore an ur-
gent need to develop new strategies to combat the spread of multi-
drug resistant infections. One of the potential options currently being
studied is the use of biostatic agents (i.e. inhibitors of bacterial growth)
that could work synergistically with existing antibiotics and boost their
efﬁcacy [3–7].Metal chelators can be used to that effect as their biostatic
activity upon microorganisms has long been known. Their mode of ac-
tion is thought to be the imposition of metal starvation on the microor-
ganisms [8–10].
The Fe3+/Fe2+ redox couple is able to catalyse a broad range of
biological reactions,[11] thus iron is an essential element ubiquitous to
virtually all organisms, making it a desirable target for the prevention
of microbial growth by chelation [12–15]. In the case of infections, the
pathogen's source of iron is known to be the hosts themselves
[16–18]. Although iron is plentiful, from the microbial perspective
there is limited bioavailability; pathogenic bacteria use efﬁcient iron
acquisition mechanisms, often based on small molecules called
siderophores [19]. Siderophores are predominantly hexadentate ferric
chelators; their Fe3+ afﬁnities/binding strengths can be very high andétard).
. This is an open access article underthus they are able to acquire otherwise unavailable iron from seques-
tered host sources [20–24]. Achieving a biostatic effect by iron starva-
tion therefore appears to depend upon a deceptively simple
thermodynamic and kinetic competition in the binding of Fe3+ cations
by the bacterial siderophores and the added chelator. Alongside the dif-
ﬁcult design of chelators that can compete effectively with
siderophores, great caremust also be taken to avoid toxic demetallation
of hostmetalloenzymes, making development of this technology a non-
trivial matter.
To competewith strong siderophores, the right choice of coordinating
groups is crucial. When considering only the thermodynamic competi-
tion between bacterial siderophores and an added chelator, onemust pri-
marily consider the respective pFe3+ values (deﬁned as−log[Fe3+]free,
usually calculated at pH7.4,with [Chelator]total=10 μMand [Fe3+]total=
1 μM and cited herein in these conditions) of the two chelators to esti-
mate which is most likely to be potent in complexing the metal [25]. It
would appear that three isomers of the hydroxypyridinone (HOPO) fam-
ily (Fig. 1) possess the right combination of pKa and logβ(Fe3+) to give
high pFe3+ values and therefore thermodynamically compete with
siderophores (that are commonly based on coordinating groups such as
α-hydroxycarboxylic acids, hydroxamic acids and catechols) [24,26].
These hydroxypyridinones also offer attractive additional prospects.
Many bacteria can use siderophores elaborated by those of another spe-
cies [18,27]; to be effective biostatic agents, synthetic chelatorsmust not
suffer from this “siderophore piracy” and actually promote bacterialthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Three relevant isomers of the HOPO family.
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been described as a siderophore ligand (1-hydroxy-5-methoxy-6-
methyl-2(1H)-pyridinone also called cepabactin), the likelihood of the
metallated chelators being recognised by bacterial receptors and
used as a source of Fe3+ is expected to be small. Additionally, infected
human hosts are known to use various Fe3+ withholding strategies
to limit bacterial growth. One of these is based on the activity of
siderocalin, a protein that in essence acts as a trap for some
siderophores [28–31]. A therapeutic chelator must not interact with
siderocalin and inhibits its protective action. It is known that some 1-
hydroxy-2(1H)-pyridinone (1.2-HOPO) based chelators do not bind
strongly to siderocalin, suggesting that this class of coordinating groups
would complement rather than overwhelm this defence strategy [32].
Members of the 3-hydroxy-4(1H)-pyridinone (3.4-HOPO) sub-
family have been extensively studied in chelation therapies [33]. A sig-
niﬁcant number of reports have also described growth inhibition of a
range of pathogenic bacteria by bidentate or hexadentate chelators
based upon 3.4-HOPO [34–43]. To achieve high pFe3+, hexadentate
chelators are preferred to bidentate ones, especially since their mode
of action as biostatic agents is expected to be extracellular and therefore
do not suffer from size restriction to penetrate the microbes. A very
small number of compounds belonging to the 1.2-HOPO sub-family
were described as antimicrobial agents [44,45] but these are all
bidentate chelators. No hexadentate member of that 1.2-HOPO sub-
family has been described as antimicrobial agent. This absence of re-
ports is surprising considering that a few hexadentate chelators based
on 1.2-HOPO were described (for complexation of non-biologically rel-
evant metals) whose structural features and chelation properties make
them attractive candidates for this purpose (for example compounds 1
and 2, Fig. 2) [46–49]. Although slightly weaker coordinating groups
than their 3-hydroxy-2(1H)-pyridinone (3.2-HOPO) and 3.4-HOPO iso-
mers, 1.2-HOPO coordinating groups possess another advantage that
make them more attractive than their isomers. Their lower pKa values
(typically 6 versus 8.5–10 depending on substitution [26]) make them
charged molecules at physiological pH and therefore less likely toFig. 2. Examples of known hexadentate chelators based on 1.2-HOPO (1, 3) and 1,4,7-trispenetrate cells of the host. This could have beneﬁcial safety beneﬁts in
treating systemic infections.
Although not based on HOPO, compound 3 has the highest known
value of pFe3+ (see below) and is therefore expected to be able to com-
pete favourably with siderophores for ferric cations at low concentra-
tion and therefore show high biostatic efﬁcacy [50]. Despite its high
pFe3+ value, to the best of our knowledge this compound has never
been described as a biostatic agent. It was therefore considered neces-
sary to synthesise, screen and use compound 3 as a benchmark.
Our interest in developing powerful Fe3+-optimised chelators as
biostatic agents prompted us to investigate a range of hexadentate
chelators based on 1.2-HOPO and a triazamacrocyclic backbone scaffold
to try to identify novel microbiostatic chelators. Very few polyaza
macrocycles bearing HOPO coordinating groups have been described
[48,51–54]. Macrocycles offer the potential to ﬁne tune the metal che-
lating properties by varying the cycle's size and fexibility. Our aim was
to combine key structural elements of siderophores, HOPO and 1,4,7-
tris(3-hydroxy-6-methyl-2-pyridylmethyl)-1,4,7-triazacyclononane
(TACN-MeHP, 3) into a novel series of chelators. In particular by analogy
with enterobactin (Fig. 3, compound 4), it is speculated that the effect of
the macrocyclic backbone scaffold could be beneﬁcial to the efﬁcacy of
metal binding and therefore to the minimum inhibitory concentration
(MIC) of the chelator. Moreover, no previous synthesis of hexadentate
chelators where 1.2-HOPOmoieties where linked to themolecular scaf-
fold via a methylene bridge were ever reported, the focus having been
on a carbonyl linker. The impact of that linker onmetal chelation efﬁca-
cy can be dramatic and therefore deserves in-depth study. Reported
herein is the synthesis of novel triaza macrocyclic chelators bearing
1.2-HOPO moieties, linked via methylene or carbonyl groups and the
study of their biostatic effect on a range of microorganisms, including
a comparison with that of known compounds 1–3.
2. Results and discussion
2.1. Organic synthesis
Our chelator design has focused on thermodynamic (pFe3+) rather
than kinetic considerations. One of the most remarkable bacterial
siderophores is enterobactin (4), whose scaffold is composed of a
triserine macrocycle (Fig. 3), and has been extensively studied owing
to its very powerful Fe3+ chelation (logβ110 = 49 and pFe3+ = 34.3,
where βmlh is deﬁned as the equilibrium constant for the reaction l
L+mM+hH+⇆ LlMmHh [25]) [55]. The origin of its efﬁcient binding
has been elucidated and shown to be inﬂuenced by the pre-organisation(3-hydroxy-6-methyl-2-pyridylmethyl)-1,4,7-triazacyclononane (TACN-MeHP) (3).
Fig. 3. Structure of siderophores enterobactin (4), bacillibactin (5) and synthetic analogue 6.
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ture of its scaffold and intra-molecular hydrogen bonding [55–59]. In-
terestingly, bacillibactin (5), a siderophore analogue of enterobactin
with glycine spacers linked to a tris-threonine macrocyclic scaffold
also shows large logβ110 and pFe3+ values (47.6, 33.1 respectively)
[55]. However, synthetic analogue 6, also composed of a glycine spacer
but of a tris-serine scaffold has poorer logβ110 and pFe3+ values (44.1
and 29.6 respectively). It would appear that the nature of the spacer
and the nature of the scaffold have a profound impact on pFe3+ that
we hypothesise as having a key inﬂuence on growth inhibition.
Compound 3 has a Fe3+ coordination environment in complexes
that is very different to that of enterobactin or HOPO-based hexadentate
chelators. Contrary to theO6donor set of 1, 2, 4, the coordination of 3 on
Fe3+ occurs through an N3O3 donor set involving the three nitrogen
atomsof the 1,4,7-triazacyclononane (TACN) ring. Asmentioned earlier,
3 has the highest known logβ110 and the highest pFe3+ values of any
known ligand (logβ110 = 49.98, pFe3+ = 39.4) and therefore is also
worthy of consideration as a potential template to improve metal che-
lating ability of the molecules [50]. Although Fe3+ coordination studies
with hexadentate analogues with a larger triaza macrocyclic cores were
not fully described, it would appear that the three nitrogen atoms are
sensibly at the right distance to efﬁciently bind the metal atom.
Inspired by these observations, andwanting to study a range of che-
lators based on 1.2-HOPO and bearing structural similarities to com-
pounds 1–3 we ﬁrst synthesised compound 7 from TACN as depicted
in Scheme 1.
The ﬁrst step in the preparation of 7 was performed based upon an
existing procedure by reacting known acyl chloride 8 with TACN in
THF [60]. Protected chelator 9was obtained in low yield (25%). RemovalScheme 1. Reagents and conditions: n= 1: (i) TACN, NEt3, THF, 60 °C; 25% (ii) Hof the benzyl groups from 9 using amixture of concentrated hydrochlo-
ric and glacial acetic acid yielded 7 in excellent yield (97%). An analogue
of that compound with the larger triaza macrocycle (i.e. 1,5,9-
triazacyclododecane, TACD) was also synthesised to allow for compari-
son of the effect of the ring size upon bacterial growth inhibition
(Scheme 1). Reaction of acyl chloride 8 with TACD in DMF allowed for
the isolation of the larger core protected molecule 11 in 49% yield. A
similar acid deprotection gave 10 in good yield (71%).
It was anticipated that the amide linkage used in 7 and 10 would
have a large impact on the conformational ﬂexibility of the chelator
[61] and also possibly an electronic effect on the 1.2-HOPO coordinating
groups. That in turn could have an important impact (either beneﬁcial
or detrimental) on Fe3+ binding but the exact effect of these linkers is
still unreported. Therefore, we also investigated the synthesis of an an-
alogue of 7, replacing the carbonyl groups by methylene units. A novel
HOPO protection strategy away from the benzyloxy protection tradi-
tionally used for 1.2-HOPO would be required. Indeed, it was predicted
that benzyl protection would not be suitable as the most common
methods used for its removal could also cleave the linkage between
our HOPO group and the molecular backbone. Of the potential protec-
tive methods identiﬁed, protection of the N-hydroxyl group as the
allyloxy group was undertaken. It was considered that deprotection
can be afforded under a range of relatively mild conditions by double
bond isomerisation and subsequent hydrolysis without compromising
other bonds in the chelator [62]. The key allyl protected 6-
hydroxymethyl intermediate 17 was synthesised in ﬁve steps from
commercially available 12 (Scheme 2) [63]. This hydroxymethyl deriv-
ative could then be converted to the novel chloromethyl derivative 17
by thionyl chloride for incorporation onto ligand cores.Cl: AcOH; 97%; n= 2: (i) TACD, NEt3, DMF, 60 °C; 49% (ii) HCl: AcOH; 71%.
Scheme 2. Reagents and conditions: (i) CH3CO3H, AcOH, 80 °C; 77% (ii) MeOH, SOCl2, reﬂux; 96% (iii) CH2CHCH2Br, K2CO3, acetonitrile, reﬂux; 94% (iv) NaBH4, MeOH, THF, reﬂux; 65%
(v) SOCl2, CH2Cl2, reﬂux; 92%.
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formed using commercially available peroxyacetic acid, a modiﬁcation
to the existing procedure of Xu et al. [60], resulting in a slightly in-
creased yield (77%) without the use of also expensive triﬂuoroacetic
acid. Treatment of the free acid 13 with thionyl chloride in methanol,
following the method of Burgada et al. [64], gave the methyl ester 14
in excellent yield (96%). Subsequent protection of the N-hydroxyl
group, using allyl bromide and potassium carbonate, yielded the novel
methyl ester 15 (94%). Reduction of the ester 15 to the methyl alcohol
16was accomplished by slow addition of methanol to sodium borohy-
dride in THF, remarkably without reduction of the allyl group [65,66].
Notably,most of these steps gave acceptable to excellent yields.Workup
of the reaction mixtures were easy to perform and the products either
needed no puriﬁcation at all or were easy to purify.
Reaction of a stoichiometric quantity of 17 with TACN in the pres-
ence of potassium carbonate produced the allyl protected macrocyclic
product 18 in a yield of 93% (Scheme 3). The removal of the allyl protec-
tive group was performed using boron trichloride, without cleavage of
the newly formed C\\Nbond, to give compound 19 as the said analogue
of 7. To the best of our knowledge, compound 19 is theﬁrst example of a
1.2-HOPOmetal chelator anchored to its scaffold via amethylene link in
position 6.
Finally, in order to discern any correlation of scaffold rigidity and
biostatic effect, the acyl chloride intermediate 8 was also reacted with
diethylenetriamine, a linear analogue of the cyclic TACN, to give chelator
20 after acid deprotection (Scheme 4).
Although chelators 1–3 were previously described in the literature
they have not been evaluated as biostatic agents therefore theirScheme3.Reagents and conditions: (i) TACN,K2CO3, CH3CN, reﬂux; 93% (ii)BCl3, CH2Cl2;
87%.synthesis was also undertaken in order to assess their antimicrobial
properties [48,49,67].
Chelator 19was considered to be an interesting compound in sever-
al respects. One of them concerns the way in which it can chelate Fe3+.
The typical mode of coordination of 1.2-HOPO-based hexadentate che-
lators on trivalent metals such as Fe3+ and Ga3+ is via the two oxygen
atoms (Fig. 4A), giving anO6 coordination environment [32]. By analogy
with derivatives of TACN-HP [68,69]but more importantly with a ligand
closely related to 19, i.e. a TACN-based tris-hydroxypyranone ligand
1,4,7-tris(3-hydroxy-6-(hydroxymethyl)-4(1H)-pyranon-2-ylmethyl)-
1,4,7-triazacyclononane (NOKA) [70], it is possible to consider another
mode of Fe3+ chelation, via a N3O3 coordination mode involving the
TACN backbone and hydroxyl groups (Fig. 4B).
To further study the exact coordinationmode of ligand 19, in partic-
ular by NMR, Ga3+ was used as a surrogate for Fe3+ [71]. No in-depth
study by MS or NMR of 1.2-HOPO based complexes of Ga(III) exist in
the literature. For example, only one derivative of 1.2-HOPO complex
(based on the 1-oxo-2-hydroxy-isoquinoline-3-carboxylic acid) of
Ga(III) has been characterised by NMR in CDCl3 [72]. Critically, no
study of the chelation by NMR or MS was performed in water, a solvent
more relevant to our growth media and where protonation reactions
can have a dramatic impact on the species formed [73]. To try and estab-
lish spectroscopic features that would allow us to distinguish an N3O3
from an O6 coordination mode, we were forced to ﬁrst investigate by
MS andNMR the complexation of Ga(III) on amodel system. Compound
22 that we described for another type of application has been selected
as such a model of ligand 19 [63].
It was judged that compound 22 in the presence of Ga(III) would
form a 3:1 complex via the six oxygen atoms of three 1.2-HOPO
bidentate ligands (Fig. 5). Therefore, compound 23 would be a good
model of the coordination environment aroundGa(III) if ligand 19 coor-
dinated Ga(III) in a O6 mode (Fig. 4A) and by extension, would give us
some information on the way Fe3+ is chelated by 19.
Proton and carbon NMR were ﬁrst performed on solutions of 22
and 19 in D2O. To these solutions, a stoichiometric amount of
Ga(acac)3 (acac = acetylacetonate) was then added and the
solutions incubated at room temperature for 24 h. The 1H and 13C
NMR of the resulting complexes were then recorded. Also, these
solutions, after dilution with methanol (non-deuterated), were
analysed by MS.
StartingwithMS, 22+Ga(acac)3 (3:1molar ratio) gavemajor peaks
that match (m/z values and isotopic distribution) the formula [(22−
3H)Ga + Na]+ at m/z 511.93 (expected 512.02), 512.93 (expected
513.02), 513.93 (expected 514.02), 515.00 (expected 515.02) and
516.00 (expected 516.02) (Fig. S1), conﬁrming the displacement of
the three acac ligands and strongly suggesting the formation of the
3:1 complex 23 as expected.
Scheme 4. Reagents and conditions: (i) diethylenetriamine, NEt3, THF, 60 °C; 91% (ii) HCl: AcOH; 70%.
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match (m/z values and isotopic distribution) the formula [(19 −
3H)Ga + H]+ at m/z 565.13 (expected 565.13), 566.13 (expected
566.13), 567.13 (expected 567.13), 568.13 (expected 568.13) and
569.07 (expected 569.13) (Fig. S2). This result conﬁrms that ligand 19
is capable of displacing the three acac ligands and that formation of a
1:1 complex occurred and that these involve the deprotonation of the
three hydroxyl groups. This result cannot allow us to differentiate be-
tween the two coordination modes mentioned above.
In NMR, we expected that coordination of the HOPO moiety to
Ga(III)would result in distinct changes to the chemical shifts of key pro-
tons and/or carbon atoms of the ligand and it was anticipated that these
could be characteristic of the two coordination modes. The 1H and 13C
NMR spectra are given in Figs. S3 and S4 respectively. The 1H of ligand
22 in D2O in the absence or presence of 1/3 molar equivalent of
Ga(acac)3 indicated that upon complexation, the three signals of the
1.2-HOPO group are shifted downﬁeld by no more than 0.3 ppm. The
1H NMR of 19+Ga(acac)3 also showed a downﬁeld shift of the chem-
ical shifts but by a larger value of 0.6 ppm. These differences could sug-
gest a different coordination mode. The presence of only one set of
slightly broaden signals for the 1.2-HOPO moiety in the case of
19+Ga(acac)3 indicates that they are all largely equivalent and there-
fore all similarly coordinating, as suggested by the mass spectrum. The
signals for the TACN scaffold are much more impacted by the presence
of the metal. Instead of well-deﬁned singlet in the ligand, various
broad signals are seen between 3.1 and 4.1 ppm. Appearance of broad
signals for In(III) complexes of NOKA has been observed at elevated
temperature (contrary to the Ga(III)NOKA complex where the signals
remained as well deﬁned multiplets even at 85 °C) [70]. This has been
ascribed to rapid exchange between theΔ andΛ isomers. The broad sig-
nals observed in our complex suggest that this rapid exchange exist
even at room temperature.
In the 13C spectrum of 22 with and without Ga(acac)3, the signal
assigned to the carbon atom of the carbonyl is also shifted, upﬁeld this
time by 3.3 ppm. Interestingly, the most impacted signals correspond
to the three C\\H groups. The 13C NMR of 19+Ga(acac)3 is drastically
different from that of the parent ligand and that of the analogousFig. 4. Possible coordination modes for compound 19 with trivalent metal M (e.g. Fe3+,
Ga3+).complex 23. Again, focusing on the signals for the TACN's methylene
group, several signals are now seen, conﬁrming the distorted nature of
the scaffold. The signals associated with the carbon atoms in the 1.2-
HOPO groups are also drastically shifted upon complexation. For
example, one signal was found at 195.4 ppm corresponding to a quater-
nary carbon atom that did not appear in the spectrum of the free ligand.
The differences between the 1H and 13C NMR of 19 and 22 with and
without Ga(III) suggest that the two ligands provide a different coordi-
nation mode. Because 22 is expected to provide an O6 coordination
environment, we tentatively suggest that an N3O3 coordination
mode exists for ligand 19 + Ga(III) and therefore by extension to
19 + Fe(III) but further work will be necessary to draw a ﬁrmer
conclusion.
2.2. Biostatic activity
We selected a small panel of diversemicrobes to assess the efﬁcacy of
these chelators; these included bacteria from both Gram negative and
Gram positive lineages as well as the pathogenic dimorphic fungus
Candida albicans. Some species were selected for their implication in
healthcare-associated infections, where possible strains previously used
in the assessment of iron chelators or pharmaceuticalswere used. Bacillus
subtilis strain DSM-23,778 lacks a key phosphopantetheinyl transferase
activity [74] required for siderophore biosynthesis and generates the
bidentate itoic acid rather than the hexadentate bacillibactin [75]. Broth
microdilution tests were undertaken based upon a standard procedure
[76]. The results obtained are shown in Table 1. The commercially
available N,N′,N′,N″,N″-diethylenetriaminepentaacetic acid (DTPA) was
also assayed for comparison purposes.
Across the range of microorganisms tested, it would appear that
compounds 1 and 3 are systematically the best inhibitors of microbial
growth (supplementary material, Table S). Compound 19 also appears
to be one of the better chelators but it failed to equal the formerFig. 5. 6-hydroxymethyl-1-hydroxy-2(1H)-pyridinone (22) and its expected 3:1 complex
with Ga(III) (23).
Table 1
Minimum Inhibitory Concentrations (MIC) expressed in μM (inmg/L between brackets) for the ligands tested upon a panel of microorganisms. Results were determined in triplicate. The
molar mass (g/mol) of each chelator is given between brackets in the ﬁrst column.
Minimum Inhibitory Concentration/μM (mg/L)
Chelator (molar
mass/g/mol)
E. coli
DSM-18039
K. pneumoniae
DSM-30104
P. aeruginosa
DSM-19880
A. baumannii
DSM-30007
B. subtilis
DSM-23778
S. aureus
DSM-1104
C. albicans
DSM-1386
DTPA (393.35) 2542 (1000) 2542 (1000) N2542 (N 1000) 2542 (1000) 159 (62.5) 79 (31.1) 318 (125.1)
1 (557.52) 625 (348.5) 313 (174.5) 313 (174.5) 313 (174.5) 313 (174.5) 5 (2.8) 313 (174.5)
2 (669.70) 5000 (3348) 5000 (3348) 5000 (3348) 1250 (837.1) 313 (209.6) 625 (418.6) 78 (52.2)
3 (492.63) 78 (38.4) 313 (154.2) 625 (307.9) 156 (76.9) 78 (38.4) 78 (38.4) 39 (19.2)
7 (537.60) 5000 (2688) N5000 (N2688) 5000 (2688) 5000 (2688) 5000 (2688) 2500 (1344) 313 (168.3)
10 (576.66) 5000 (2883) 5000 (2883) 2500 (1442) 313 (180.5) 1250 (720.8) 625 (360.4) 39 (22.5)
19 (492.63) 625 (307.9) 1250 (615.8) 625 (307.9) 313 (154.2) 313 (154.2) 313 (154.2) 39 (19.2)
20 (511.56) 5000 (2558) N5000 (N2558) 5000 (2558) 1250 (639.5) 313 (160.1) 313 (160.1) 313 (160.1)
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performing chelators of this series. Interestingly, compound 10 per-
forms poorly against E. coli but verywell against C. albicans. If the efﬁca-
cy of the chelators was simply linked to the thermodynamics of their
Fe3+ chelation (e.g. pFe3+), one could expect to observe the same
rank ordering across the microorganism panel, the interspecies varia-
tions in MIC being indicative of the capacity of each microbe to deal
with the ﬁnite competitive challenge deﬁned by the chelator dose. The
fact that 1, 3, 19 appear to be the most effective inhibitors and 2, 7
and 20 the poorest but that the efﬁcacy of 10 appears variable suggests
that strength of metal chelation, if dominant, is not the only factor that
inﬂuences themeasuredMIC values. The fact that pFe3+ only takes into
consideration iron chelation (while bacteria rely on other biologically
relevant metals, e.g. Cu2+, Zn2+ that can also be chelated more or
less efﬁciently by the added chelators) and does not includes kinetics ef-
fects (e.g. metallation of the chelator, siderophores and potential
transmetallation reactions) may explain these observations.
The chelators' ranking does not appear to be different between
Gram-positive and Gram-negative bacteria in the screened set. Howev-
er, it would appear that the MIC values obtained on the four tested
Gram-negative bacteria are higher than on the tested Gram-positive
bacteria. It would appear that our strains of S. aureus and C. albicans
were more sensitive to the presence of a chelator than the other micro-
organisms, up to two orders of magnitude for S. aureus (supplementary
materials, Table S2). On the contrary the strains of P. aeruginosa,
K. pneumonia and E. coli appear to be themost resistant of all the organ-
isms tested to the presence of the chelators. Both E. coli [77,78] and
K. pneumoniae [79,80] produce enterobactin (4), the most powerful
known siderophore and therefore they are expected based on thermo-
dynamic considerations to have a high degree of tolerance for added
chelators. However, arguably the greatest resistance is exhibited by
P. aeruginosa which produces the less potent chelators, pyoverdins
and pyochelin [81] rather than enterobactin. These siderophores are
not expected to thermodynamically compete favourably with chelators
such as 3. Unless in the future it is found that P. aeruginosa as suggested
displays “still-unexplored uptake capabilities” [12], or secretes powerful
(but still unidentiﬁed) siderophores, this result would suggest that
there are other factors at play than simple thermodynamically compet-
ing chelation reactions.
The greater susceptibility of Gram-positive bacteria to added chela-
tor than Gram-negative has already been observed [42] and suggested
to be due to the barrier function of Gram-negative outermembrane pre-
sented tomolecules of this size (molarmasses in Table 1). However, we
argue here that the chelators' contribution to biostasis is likely extracel-
lular, in chelating the metal in the growth medium and therefore that
the differential susceptibility of Gram-positive and Gram-negative bac-
teria is due to other factors. The susceptibility of B. subtilis DSM-23,778
to these metal chelators is in contrast to the resilience of two Bacillus
species (B. subtilis and Benthesicymus cereus) to 3.4-HOPO-based
hexadentate chelators [42]. However, these were wild isolates thatmay have had the ability to produce the hexadentate siderophore
bacillibactin. It should be noted that B. subtilis DSM-23,778 was chosen
here for its synthetic limitation to a bidentate siderophore [75] rather
than its cellular architecture, so the data presented here should not be
considered in arguments surrounding efﬁcacy and the possession of
an outer membrane. Furthermore, the size and composition of the mi-
crobial panels tested here and elsewhere [42] are limited and such
mechanistic detail will require careful design of more extensive experi-
ments than were appropriate in this preliminary study.
As the siderophores produced by each of these bacterial strains have
not all been formally identiﬁed and/or their Fe3+ binding efﬁcacy mea-
sured, it is not yet possible to determine with a high level of conﬁdence
whether the bacteria most resistant to external chelators are systemat-
ically the ones that produce the strongest siderophores (highest pFe3+).
Also, for each siderophore, its pFe3+ is inﬂuenced by its total concentra-
tion and these can vary over time and as a function of the ability of the
microorganism to excrete them in large quantity.
The poor range of hexadentate chelators based on 1.2-HOPO de-
scribed in the literature needs to be addressed if these are to be seriously
considered in therapeutic applications. Consideration of the high efﬁca-
cy of chelator 19, where theHOPO group is linked to the TACN core via a
methylene group, and the poor efﬁcacy of 7, where the linker is a car-
bonyl, suggests that optimisation of the linker will be critical. Compari-
son of chelators 1, 7 and 19 suggest that the use of a more rigid
macrocyclic scaffold compared to the tris(2-aminoethyl)amine core
(to promote chelation via entropic effects) was not successful in im-
proving biological activity.
All the HOPO-based chelators tested herein were designed with the
goal of optimising Fe3+ chelation. This does not mean that trapping of
other essential metals is not concomitantly achieved that leads to the
biostatic effect. The amount of key metals in the growth medium was
measured and found to be 65.7 μM for iron, 31.5 μM for zinc, 13.7 μM
for manganese, 8.3 μM for cobalt and 4.5 μM for copper. For all the mi-
croorganisms tested except C. albicans, the MIC is above the concentra-
tion of iron, as would be expected if our hypothesised mechanism of
action is valid. However, the MIC observed on C. albicans of 39 μM for
3, 10 and 19 suggests either that partial chelation of iron is enough to
have a biostatic effect on that microorganism or that our chelator also
targets other metals that have a much more dramatic effect on its
growth or that it affects the organism in a manner not related to metal
limitation.
Finally, the effect of added chelators on the availability of other bio-
logically important metals must also be taken into consideration as
discussed above. It is therefore unwise to try and rationalise the data
presented herein based on relative pFe3+ values. Progress towards an
understanding of their mode of action however can bemade by consid-
ering the siderophores that are known to be produced by the tested or-
ganisms. Further work is in progress to investigate in depth the
mechanism of action of these chelators and to correlate their activity
to the thermodynamics and kinetics of their metal binding.
Fig. 6. Impact of sub MIC concentrations on growth of selected bacteria. Panel A describes
K. pneumoniae DSM-30,104 grown with 3; Panels B and C describe, P. aeruginosa DSM-
19,880 (B) and A. baumanii DSM-30,007 (C) both grown with 19. In each case, MIC
(green, (1)) and two sub-MIC concentrations were followed: MIC/4 (red, (3)), MIC/2
(blue, (2)), and the untreated control (black, (4)). Readings were taken every 20 min.
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ganisms was followed by optical density (Fig. 6).
As expected each microorganism in the absence of the added chela-
tor, shows a lag phase before entering exponential growth. In the pres-
ence of the added chelator, the lag phase appears longer in some cases
(e.g. K. pneumoniae + 3 at MIC/4) but is not substantially increased in
the other cases tested, although a decrease in growth rate is evident.
In all the tested cases and by deﬁnition, the lag phase was over 24 h
when the chelator was used at theMIC value derived from the previous
assays. What is apparent for all tested combination is that the rate ofgrowth is signiﬁcantly reducedwith increasing concentrations of chela-
tors. These growth proﬁles are consistentwith the expectedmode of ac-
tion of the chelators. The microorganisms that suffer from the biostatic
effect of a metal chelator ﬁnd themselves in iron deprivation conditions
due to the presence of the said chelator. They therefore have to produce
a large amount of siderophore to compete and only when the chelator's
pFe3+ is overcome by the siderophore's pFe3+ valuewill any growth be
initiated. The higher the amount of chelator, the longer it takes the
microorganisms to overcome the effect of the biostatic agent. This is
consistentwith the hypothesis the compounds operate as an extracellu-
lar chelator.3. Conclusion
We report the synthesis of a range of hexadentate chelators based on
triazamacrocycles, including theﬁrst report of the use of amethylene as
a linker between a 1.2-HOPO coordinating group and the molecular
scaffold. The ligands have a demonstrable biostatic effect upon the
growth of a range of microbes. It is suggested that metal chelation is
themain mode of action of these chelators but that a simple thermody-
namic competition between the chelator and bacterial siderophore for
Fe3+ is too simple a picture. Further work is in progress to understand
the mode of action of these chelators in detail and to synthesise a
wider range of hexadentate chelators based on 1.2-HOPO to assess
their efﬁcacy as biostatic agents. These compounds will also form the
basis for the study of the effect of the linker between the 1.2-HOPO
moiety and the molecular backbone on the thermodynamic efﬁcacy of
Fe3+ chelation via measurements of pKa and β110 values.4. Experimental
4.1. Preparation of stock solutions
Glassware was rinsed with a deionised aqueous solution of EDTA
(0.1M) then rinsed thoroughlywith deionisedwater (18mΩ) before li-
gands were dissolved in deionised water to the desired concentration
(5mM; 5mL). The stock solutionwas then passed through amembrane
ﬁlter (0.22 μM) into a sterile bijoux tube (7 mL) and stored at 4 °C until
required.4.2. Bacterial strains
All strains were purchased from DSMZ. E. coli DSM-18,039,
K. pneumoniae DSM-30,104, P. aeruginosa DSM-19,880 and S. aureus
DSM-1104were cultured onto brain heart infusion (BHI) agar and incu-
bated at 37 °C for 24 h. Similar procedures were conducted for strains of
A. baumannii DSM-30,007 and C. albicans DSM-1386 incubated at 30 °C
and B. subtilis incubated at 25 °C, all for 48 h. The cultured plates were
then stored at 4 °C until needed.4.3. Antimicrobial assay
The assay conducted was based upon a similar literature procedure
[76]. Stock solutions of ligands (5000 μM) were added to the ﬁrst
wells of a 96 well-microtitre plate (200 μL) and sterile BHI broth
(100 μL) was added to the remaining wells in the row. Ligand solution
from the ﬁrst well (100 μL) was added to the next well in the row and
mixed. The procedure was then repeated along the row from the
dilute solutions and discarded after the penultimate well. Inoculum
(105 CFU/mL; 100 μL)was then added to all wells and the plate incubat-
edwithout agitation at 37 °C. Readings were taken after for 24 and 48 h,
depending upon the microorganism, and the MIC determined on the
basis of visual turbidity of the well. Assays were performed in triplicate.
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All solvents and reagents were purchased from Sigma-Aldrich, Acros
Organics or Alfa-Aeser and usedwithout further puriﬁcation unless oth-
erwise speciﬁed. Reactions were followed by TLC using silica gel with
UV254 ﬂuorescent indicator and column chromatography was conduct-
ed using 0.060–0.20 mm silica gel (70–230 mesh), where automated
ﬂash column chromatography was conducted using a Biotage Isolera
One ISO1SV. Hydrogenations performed using an H-cube® continuous
ﬂow hydrogen generator was operated as speciﬁed.4.5. Physical measurements
Melting pointswere taken on a SRSDigiMeltMPA161digitalmelting
point apparatus with samples prepared in SAMCO soda glass capillary
tubes 100 mm. NMR spectra were recorded using a Jeol JNM Ex270 in-
strument at 270 MHz and 68 MHz or a Jeol JNM-ECS400 instrument at
400 MHz and 100 MHz, as speciﬁed, for 1H and 13C NMR respectively,
and are reported in ppm (δ). Infrared spectra were obtained using
Durascope diamond ATR system on a Perkin Elmer RX1 FTIR spectrom-
eter. Positive and negative electrospray ionisation mass spectrometry
(ESI-MS) was conducted using a Thermo LCQ Advantage mass spec-
trometer by direct injection. High resolution mass spectrometry were
obtained in a Finnigan MAT900XLT high-resolution double focussing
mass spectrometer using nano-electrospray ionisation (NESI) at the
EPSRC National Mass Spectrometry Service (University of Swansea,
Wales, UK). UV–Visible spectrophotometry was conducted using a
Varian Cary 50 UV–vis spectrophotometer (range 200–800 nm) using
a 1 cmquartz cell at room temperature (18–22 °C). Optical density read-
ings were taken using a Biotek HTMulti-modeMicroplate reader at the
wavelength speciﬁed. Compounds 1 [49], 2 [48], 3 [67] and 8 [60] were
synthesised as described. TACN was synthesised using the Richman-
Atkins method with slight modiﬁcation [82,83]. TACD was prepared
via modiﬁcation to the methodology developed by Alder et al. [84,85].4.5.1. 1-Hydroxy-6-oxo-1.6-dihydropyridine-2-carboxylic acid (13)
Using amodiﬁed version of a literaturemethod [60], to a suspension
of 6-hydroxypicolinic acid 12 (26.20 g, 188 mmol) in glacial acetic acid
(160 mL) was carefully added peroxyacetic acid (36–40%, 80 mL). The
temperature was carefully raised to 80 °C and stirring was continued
for 12 h. The ﬂask was allowed to cool to room temperature and the
resulting solid precipitate was collected by ﬁltration and washed with
diethyl ether, affording the title compound 13 as a cream solid
(18.17 g, 77%). Mp 223–226 °C (from AcOH, Lit [64]. 216 °C).
vmax(neat)/cm−1 3114 (O\\H), 1611 (CO), 1505 (CO), 1198.
δH(399.8 MHz, DMSO-d6) 6.65 (1H, dd, J 7.3, 1.8, 3-H), 6.73 (1H, dd, J
9.2, 1.8, 5-H), 7.46 (1H, dd, J 8.7, 6.9, 4-H). δC(100.5 MHz, DMSO-d6)
106.8 (ArC), 120.8 (ArC), 137.3 (ArC), 139.5 (quat), 157.7 (quat),
162.4 (quat).4.5.2. Methyl 1-hydroxy-6-oxo-1.6-dihydropyridine-2-carboxylate (14)
[64]
To a suspension of acid 13 (15.73 g, 101 mmol) in methanol
(200 mL) at 0 °C was added thionyl chloride (31.00 g, 426 mmol)
dropwise. The mixture was heated under reﬂux for 4 h. The solution
was then allowed to cool to room temperature and the solvent was re-
moved in vacuo to afford the title compound 14 as a cream solid
(16.47 g, 96%). Mp 106–108 °C (from MeOH, Lit [64]. 90–92 °C).
vmax(neat)/cm−1 3115 (O\\H), 1732 (CO), 1505 (CO), 1204.
δH(399.8 MHz, DMSO-d6) 3.87 (3H, s, CO2CH3), 6.53 (1H, dd, J 6.9, 1.4,
3-H), 6.69 (1H, dd, J 9.2, 1.4, 5-H), 7.45 (1H, dd, J 9.2, 6.9, 4-H).
δC(100.5 MHz, DMSO-d6) 53.8 (CO2CH3), 105.8 (ArC), 122.6 (ArC),
137.8 (ArC), 138.8 (quat), 158.1 (quat), 161.4 (quat).4.5.3. Methyl 6-oxo-1-(allyloxy)-1.6-dihydropyridine-2-carboxylate (15)
To a solution of compound 14 (16.47 g, 97 mmol) in acetonitrile
(200mL) was added potassium carbonate (32.11 g, 232mmol), follow-
ed by allyl bromide (28.10 g, 232mmol). The ﬂaskwas heated under re-
ﬂux for 4 h before the reaction mixture was ﬁltered and the solvent
removed under high vacuum. The residue was dissolved in toluene
(100 mL) and the solvent was evaporated in vacuo to afford the title
compound 15 as a white crystalline solid (19.12 g, 94%). Mp 65–67 °C
(from toluene). Found C, 57.06; H, 5.38; N, 6.67%; C10H11NO4 requires
C, 57.41; H, 5.30; N, 6.70%. vmax(neat)/cm−1 3462, 3078, 2953, 1735
(CO), 1661 (CO), 1586 (CC), 1445, 1275, 1209, 1136. δH(399.8 MHz,
DMSO-d6) 3.94 (3H, s, CO2CH3), 4.90 (2H, d, J 6.9, CH2CHCH2), 5.42
(2H, m, CH2CHCH2), 6.08 (1H, m, CH2CHCH2), 6.53 (1H, dd, J 6.9, 1.8,
3-H), 6.80 (1H, dd, J 9.2, 1.8, 5-H), 7.31 (1H, dd, J 9.6, 6.9, 4-H).
δC(100.5 MHz, DMSO-d6) 53.3 (CH2CHCH2), 78.1 (CO2CH3), 107.9
(CH2CHCH2), 121.9 (CH2CHCH2), 126.0 (ArC), 130.6 (ArC), 137.2
(ArC), 138.7 (quat), 158.8 (quat), 160.6 (quat). m/z (NESI) 210.0759
([M + H]+); C10H12NO4 requires 210.0766.
4.5.4. 6-(Hydroxymethyl)-1-(allyloxy)pyridin-2(1H)-one (16)
To a suspension of compound 15 (19.12 g, 92 mmol) in THF
(200 mL) was added solid sodium borohydride (25.07 g, 663 mmol)
in small portions. The solution was heated under reﬂux for 15 min.
Methanol (14 mL) was then added dropwise at reﬂux over 2 h. The so-
lutionwas then cooled to 0 °C, quenched by careful addition of saturated
aqueous ammonium chloride (25 mL) and stirring was continued for
15 min. The solvents were removed in vacuo and the residue was ex-
tracted with dichloromethane (3 × 25 mL). The combined organic ex-
tracts were dried and evaporated to afford the title compound 16 as
an off-white solid (10.83 g, 65%). Mp 101–104 °C (from DCM). Found
C, 59.23; H, 6.23; N, 7.59%; C9H11NO3 requires C, 59.66; H, 6.12; N,
7.73%. vmax(neat)/cm−1 3198 (O\\H), 2896, 2842, 1650 (CO), 1560
(CC), 1441, 1154, 1093. δH(399.8 MHz, CDCl3, Me4Si) 2.74 (1H, t, J 6.4,
CH2OH), 4.68 (2H, d, J 6.4, CH2OH), 4.84 (2H, d, J 6.4, CH2CHCH2), 5.43
(2H, m, CH2CHCH2), 6.06 (1H, m, CH2CHCH2), 6.24 (1H, d, J 6.9, 3-H),
6.50 (1H, dd, J 9.2, 1.4, 5-H), 7.30 (1H, dd, J 9.2, 6.9 4-H).
δC(100.5 MHz, CDCl3, Me4Si) 59.4 (CH2CHCH2), 103.7 (CH2CHCH2),
120.4 (CH2CHCH2), 122.6 (ArC), 130.3 (ArC), 138.7 (ArC), 148.9
(quat), 159.7 (quat). m/z (NESI) 182.0811 ([M + H]+); C9H12NO3 re-
quires 182.0817.
4.5.5. N,N′,N″-tris(1-benzyloxy-6(1H)-pyridinone-2-carbonyl)-1,4,7-
triazacyclononane (9)
Following a reported procedure [60] a solution of TACN (0.21 g;
1.6 mmol) and 8 (1.42 g, 8.2 mmol) in dry tetrahydrofuran (40 mL)
was added triethylamine (0.55 g, 5.4 mmol) and stirred at 60 °C for
16 h after which the mixture was concentrated to dryness in vacuo.
The residue was then partitioned betweenwater (50mL) and dichloro-
methane (50 mL) and the organic layer washed with aqueous hydro-
chloric acid (1 M; 50 mL), aqueous sodium hydroxide (1 M; 50 mL)
and brine (50 mL). The organic layer was then dried using magnesium
sulfate and ﬁltered before solvent removal in vacuo. Puriﬁcation of the
resulting residue by automated ﬂash chromatography (dichlorometh-
ane: methanol, 0–10%) yielded the product as a white solid (0.36 g,
25%); mp 164–170 °C. δH (400 MHz; CDCl3; Me4Si) 2.07–4.26 (12H,
mm) 4.81 (1H, d, J 8.2 Hz) 4.87 (1H, d, J 8.7 Hz) 5.04 (1H, m) 5.49–
6.06 (5H, mm) 6.68–6.89 (7H, mm) 7.28–7.60 (16H, m); δC
(100 MHz) 47.9, 48.8, 49.2, 49.8, 77.1, 79.2, 79.7, 80.0, 102.7, 103.3,
123.4, 123.5, 123.6, 128.6, 128.7, 128.8, 129.1, 129.4, 130.1, 130.6,
131.0, 131.3, 132.4, 133.1, 133.8, 137.9, 138.3, 138.4, 140.8, 141.5,
141.9, 157.9, 158.0, 162.9, 163.0, 163.2; (+)-ESI-MS: m/z 833.01
(M+ Na+); NESI: requires;m/z 811.3092, found 811.3086 (M+ H+).
4.5.6. 6-(Chloromethyl)-1-(allyloxy)-2(1H)-pyridinone (17)
A solution of 16 (4.88 g, 27mmol) in dichloromethane (120mL)was
added thionyl chloride (12 mL, 165 mmol) and reﬂuxed for 6 h. Ice
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were then separated and the aqueous phase was extracted with dichlo-
romethane (2 × 100 mL). The combined organic phases were dried
using magnesium sulfate, ﬁltered and solvent removed in vacuo, yield-
ing a brown oil which solidiﬁed upon standing (4.95 g, 92%); mp 62–
65 °C. δH (400 MHz; CDCl3; Me4Si) 4.57 (2H, s) 4.93 (2H, d, J 6.7 Hz)
5.47 (2H, m) 6.12 (1H, m) 6.25 (1H, dd, J 1.7, 6.7 Hz) 6.68 (1H, dd, J
1.7, 9.2 Hz) 7.27 (1H, dd, J 7.0, 9.4 Hz); δC (100 MHz) 39.5, 77.5106.4,
122.5, 123.1, 130.3, 137.8, 144.3, 159.3; NESI: requires; m/z 200.0478,
found; 200.0472 (M+).
4.5.7. N,N′,N″-tris(1-hydroxy-6(1H)-pyridinone-2-carbonyl)-1,4,7-
triazacyclononane (7)
A solution of 9 (0.358 g, 0.44 mmol) in a concentrated hydrochloric
acid: glacial acetic acid mixture (1: 1; 12 mL) was stirred for 4 days at
room temperature then for 2 days at 50 °C. Solvent removal in
vacuo yielded a white solid foam (0.230 g, 97%); mp N260 °C. δH
(400 MHz; [D6]-DMSO; Me4Si) 3.03–3.82 (12H, m) 6.12–6.35 (2H,
m) 6.37–6.63 (4H, m) 7.11 & 7.23 (1H, m) 7.29–7.48 (4H, m); δC
(100 MHz) 48.4–49.6 (m), 103.1 (m), 120.1, 138.4 (m), 141.7, 157.8–
158.0, 163.3; (+)-ESI-MS: m/z 541.13 (M + H+) 563.10 (M + Na+);
NESI: requires; m/z 563.1502, 541.1683, found; 563.1490 (M + Na+)
541.1672 (M+ H+).
4.5.8. N,N′,N″-tris(1-allyloxy-6(1H)-pyridinone-2-methyl)-1,4,7-
triazacyclononane (18)
A mixture of 17 (0.448 g, 2.24 mmol), potassium carbonate (0.41 g,
3.0 mmol) and TACN (0.095 g, 0.74 mmol) in acetonitrile (20 mL) was
reﬂuxed overnight. The mixture was then added to water (50 mL) be-
fore extraction with dichloromethane (3 × 50mL). The organic extracts
were washed with brine (50 mL) before being dried with magnesium
sulfate and the solvent removed in vacuo to yield a dark orange highly
viscous liquid (0.431 g, 93%). δH (400 MHz; CDCl3; Me4Si) 2.87 (12H,
s) 3.72 (6H, s) 4.79 (6H, d, J 6.4 Hz) 5.38 (6H, m) 6.05 (3H, m) 6.15
(3H, dd, J 1.4, 6.9 Hz) 6.56 (3H, dd, J 1.4, 9.2 Hz) 7.24 (3H, dd, J 6.9,
9.2 Hz); δC (100 MHz) 55.9, 57.1, 76.7, 104.8, 120.4, 122.1, 130.5,
137.9, 147.7, 159.7; (+)-ESI-MS:m/z 619.05 (M+H+); NESI: requires;
m/z 619.3244, found; 619.3243 (M+ H+).
4.5.9. N,N′,N″-tris(1-hydroxy-6(1H)-pyridinone-2-methyl)-1,4,7-
triazacyclononane. 3 HCl (19)
Under an atmosphere of nitrogen, a solution of 18 (0.759 g,
1.2 mmol) in dry dichloromethane (8 mL) at 0 °C was added boron
trichloride in hexane (1.0 M; 8.6 mL, 8.6 mmol) and vigorously stirred
overnight before the mixture was added methanol (8 mL) and stirred
for 30 min further. The solution was then evaporated in vacuo and re-
evaporated with methanol (10 mL) 5 times, yielding the crude as
brown ﬂakes. Dissolution in a minimum volume of methanol and pre-
cipitation using diethyl ether yielded a cream solid following collection
by Büchner ﬁltration andwashingwith diethyl ether (0.534 g, 87%), mp
180 °C (decomp.). δH (400 MHz; [D6]-DMSO; Me4Si) 3.01 (12H, s) 4.18
(6H, s) 6.34 (3H, dd, J 1.4, 6.9 Hz) 6.54 (3H, dd, J 1.4, 9.2 Hz) 7.39 (3H, dd,
J 6.9, 9.2 Hz); δC (100 MHz) 49.3, 53.1, 106.8, 118.5, 137.5, 141.9, 158.5.
4.5.10. N,N′,N″-tris(1-benzyloxy-6(1H)-pyridinone-2-carbonyl)-1,5,9-
triazacyclododecane (11)
Product was prepared based upon a similar literature procedure
[60]. To a solution of TACD (0.18 g; 1.1 mmol) and triethylamine
(0.46 g, 4.5 mmol) in dry N,N-dimethylformamide (5 mL) was added
8 (0.89 g, 3.4 mmol) and was stirred at 60 °C in a stoppered ﬂask for
48 h. After this time the mixture was concentrated to dryness in vacuo
and the residue was dissolved in dichloromethane (50 mL) before
being washed with aqueous hydrochloric acid (1 M; 50 mL), aqueous
sodium hydroxide (1 M; 50 mL), water (3 × 50 mL) and brine
(50 mL). The organic layer was then dried using magnesium sulfate
and ﬁltered before solvent removal in vacuo. Puriﬁcation of theresulting residue by automated ﬂash chromatography (dichlorometh-
ane: methanol, 1–6%) yielded the product as a white solid (0.44 g,
49%); mp 118–123 °C. δH (400 MHz; CDCl3; Me4Si) 0.89–3.94 (18H,
mm) 4.83–5.04 (3H, mm) 5.38–6.04 (5H, mm) 6.64–7.18 (4H, mm)
7.25–7.58 (18H, mm); δC (100 MHz; CDCl3; Me4Si) 24.5, 25.5, 25.9,
26.6, 27.0, 28.8, 31.4, 36.5, 42.2, 44.6, 45.7, 45.8, 46.3, 46.6, 46.8, 48.5,
49.2, 79.3, 79.4, 79.5, 79.7, 102.2, 102.3, 102.5, 102.6, 102.7, 123.0,
123.1, 123.2, 123.3, 123.4, 128.4, 128.5, 128.7, 128.8, 129.0, 129.2,
129.4, 129.5, 129.7, 129.9, 130.0, 130.0, 130.2, 130.3, 130.5, 130.7,
130.7, 131.3, 133.1, 133.4, 133.5, 133.6, 133.7, 133.8, 137.2, 138.0,
138.0, 138.1, 138.2, 138.3, 138.4, 138.5, 138.5, 141.9, 142.2,
142.3142.4, 142.6, 142.6, 142.6, 142.7, 158.0, 158.1, 158.1, 158.2,
158.2, 161.9, 162.0, 162.1, 162.4, 162.5, 163.0; (+)-ESI-MS: m/z
875.16 (M + H+); NESI: requires; m/z 875.3380, 853.3561; found;
875.3366 (M+ Na+) 853.3555 (M+ H+).
4.5.11. N,N′,N″-tris(1-benzyloxy-6(1H)-pyridinone-2-carbonyl)-1,5,9-
triazacyclododecane (10)
A solution of 11 (0.268 g, 4.3mmol) in amixture of concentrated hy-
drochloric acid and glacial acetic acid (1: 1; 12 mL) was stirred at ambi-
ent temperature for 4 days before stirring overnight at 50 °C. The
solution was then concentrated to dryness in vacuo before dissolution
in a minimum volume of methanol and solid precipitation by diethyl
ether addition. The product was collected by Büchner ﬁltration and
washed with diethyl ether yielding a white powder (0.130 g, 71%);
mp 161–169 °C. δH (400 MHz; [D6]-DMSO; Me4Si) 1.78–2.15 (6H, m,
br) 2.96–3.52 (12H, m, br) 6.17–6.34 (3H, m, br) 6.49–6.59 (3H,
m) 7.32–7.47 (3H, m); δC (100 MHz) 42.7, 43.4, 46.5, 47.6, 82.9, 102.0,
119.0, 137.5, 137.6, 137.6, 141.5, 141.6, 141.6, 157.2, 157.2, 161.8,
162.1; (−)-ESI-MS: m/z 581.16 ([M − H]−), HRMS NESN: requires;
581.1996, found; 581.1985 ([M− H]−).
4.5.12. N,N′,N″-tris(1-benzyloxy-6(1H)-pyridinone-2-carbonyl)-bis(2-
aminoethyl)amine (21)
Product was prepared based upon a similar literature procedure
[60]. A mixture of 8 (1.29 g, 4.9 mmol) and triethylamine (1.35 g,
13.3 mmol) in dry tetrahydrofuran (20 mL) was added
diethylenetriamine (0.15 g, 1.5 mmol) and stirred in a stoppered
ﬂask overnight at 60 °C. The mixture was then concentrated to dry-
ness in vacuo and the residue dissolved in a mixture of water
(100 mL) and dichloromethane (100 mL). Separation of the phases
and washing of the organic layer with aqueous sodium hydroxide
(1 M; 100 mL), aqueous hydrochloric acid (1 M; 100 mL) then brine
(100mL) before drying overmagnesium sulfate, ﬁltration and solvent re-
moval in vacuo yielded the crude residuewhichwas puriﬁed by automat-
ed ﬂash chromatography (dichloromethane: methanol, 1–11%) yielding
the product as a hygroscopic solid (1.04 g, 91%); mp 84–89 °C. δH
(400 MHz; CDCl3; Me4Si) 3.04–3.28 (6H, m) 3.48 (1H, d, J 4.1 Hz) 3.84
(1H, m) 4.94 (1H, d, J 7.8 Hz) 5.21 (1H, d, J 8.7 Hz) 5.29–5.40 (4H,
m) 5.63 (1H, d, J 7.8 Hz) 6.03 (1H, dd, J 1.8, 6.9 Hz) 6.14 (1H, dd, J 1.4,
6.9 Hz) 6.19 (1H, dd, J 1.4, 6.9 Hz) 6.60 (1H, dd, J 1.4, 9.2 Hz) 6.65 (1H,
t, J 5.5 Hz) 6.71 (1H, dd, J 1.4, 9.2 Hz) 7.17 (1H, dd, J 6.4, 9.2 Hz) 7.22
(1H, dd, J 6.4, 9.2 Hz) 7.25 (1H, dd, J 6.4, 9.2 Hz) 7.30–7.33 (10H,
m) 7.41–7.44 (4H, m) 7.49–7.52 (2H, m); δC (100 MHz) 38.2, 45.8, 48.5,
79.2, 79.3, 79.4, 103.1, 105.6, 105.9, 123.3, 124.5, 124.7, 128.7, 128.7,
129.5, 129.6, 129.7, 130.1, 130.4, 130.5, 133.2, 133.3, 133.5, 137.9, 137.9,
138.4, 141.9, 141.9, 142.0, 145.6, 158.0, 158.4, 160.7, 161.0, 163.0; (+)-
ESI-MS: m/z 807.02 (M + Na+); NESI: requires; m/z 785.2935, found;
785.3272 (M+ H+).
4.5.13. N,N′,N″-tris(1-hydroxy-6(1H)-pyridinone-2-carbonyl)-bis(2-
aminoethyl)amine (20)
A solution of 21 (0.35 g, 0.46mmol) in amixture of concentrated hy-
drochloric acid and glacial acetic acid (1: 1; 12 mL) was stirred at room
temperature for 4 days before solvent removal in vacuo. The crude solid
was then dissolved in a minimum volume of methanol and precipitated
58 D.G. Workman et al. / Journal of Inorganic Biochemistry 160 (2016) 49–58by addition of diethyl ether, yielding an off-white powder collected by
Büchner ﬁltration (0.16 g, 70%). δH (400 MHz; [D6]-DMSO; Me4Si)
3.37 (4H, s, br) 3.48 (4H, s, br) 6.28 (3H, m) 6.56 (2H, m) 7.33–7.39
(3H, m) 8.85 (1H, t, br) 8.93 (1H, t, br); δC (100 MHz) 37.0, 37.8, 44.5,
47.8, 102.9, 104.3, 104.6, 119.8, 120.1, 137.7, 137.9, 138.3, 142.0, 142.3,
142.6, 157.9, 158.0, 160.9, 161.1, 162.4, 162.9, 172.6; (+)-ESI-MS: m/z
537.09 (M + Na+); HRMS NESN: requires; m/z 513.1370, found;
513.1376 (M− H)−.
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